Cargando…

Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes

AIMS/INTRODUCTION: Limited studies have identified risk factors linked to the progression of diabetic peripheral neuropathy (DPN) in type 2 diabetes. This study examined the association of risk factors with change in neuropathy measures over 2 years. MATERIALS AND METHODS: Participants with type 2 d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponirakis, Georgios, Al‐Janahi, Ibrahim, Elgassim, Einas, Gad, Hoda, Petropoulos, Ioannis N, Khan, Adnan, Ali, Hamda, Siddique, Mashhood A, Gul, Wajiha, Ferdousi, Maryam, Kalteniece, Alise, Mohamed, Fatima FS, Ahmed, Lina HM, Dakroury, Youssra, El Shewehy, Abeer MM, Al‐Mohamedi, Abdulrahman, AlMarri, Fatema, Homssi, Moayad, Qazi, Murtaza, Hadid, Nebras H, Al‐Khayat, Fatima, Mahfoud, Ziyad R, Azmi, Shazli, Alam, Uazman, Zirie, Mahmoud A, Al‐Ansari, Yousuf, Jayyousi, Amin, Rigby, Alan S, Kilpatrick, Eric S, Atkin, Stephen L, Malik, Rayaz A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533053/
https://www.ncbi.nlm.nih.gov/pubmed/35652859
http://dx.doi.org/10.1111/jdi.13864
_version_ 1784802258533220352
author Ponirakis, Georgios
Al‐Janahi, Ibrahim
Elgassim, Einas
Gad, Hoda
Petropoulos, Ioannis N
Khan, Adnan
Ali, Hamda
Siddique, Mashhood A
Gul, Wajiha
Ferdousi, Maryam
Kalteniece, Alise
Mohamed, Fatima FS
Ahmed, Lina HM
Dakroury, Youssra
El Shewehy, Abeer MM
Al‐Mohamedi, Abdulrahman
AlMarri, Fatema
Homssi, Moayad
Qazi, Murtaza
Hadid, Nebras H
Al‐Khayat, Fatima
Mahfoud, Ziyad R
Azmi, Shazli
Alam, Uazman
Zirie, Mahmoud A
Al‐Ansari, Yousuf
Jayyousi, Amin
Rigby, Alan S
Kilpatrick, Eric S
Atkin, Stephen L
Malik, Rayaz A
author_facet Ponirakis, Georgios
Al‐Janahi, Ibrahim
Elgassim, Einas
Gad, Hoda
Petropoulos, Ioannis N
Khan, Adnan
Ali, Hamda
Siddique, Mashhood A
Gul, Wajiha
Ferdousi, Maryam
Kalteniece, Alise
Mohamed, Fatima FS
Ahmed, Lina HM
Dakroury, Youssra
El Shewehy, Abeer MM
Al‐Mohamedi, Abdulrahman
AlMarri, Fatema
Homssi, Moayad
Qazi, Murtaza
Hadid, Nebras H
Al‐Khayat, Fatima
Mahfoud, Ziyad R
Azmi, Shazli
Alam, Uazman
Zirie, Mahmoud A
Al‐Ansari, Yousuf
Jayyousi, Amin
Rigby, Alan S
Kilpatrick, Eric S
Atkin, Stephen L
Malik, Rayaz A
author_sort Ponirakis, Georgios
collection PubMed
description AIMS/INTRODUCTION: Limited studies have identified risk factors linked to the progression of diabetic peripheral neuropathy (DPN) in type 2 diabetes. This study examined the association of risk factors with change in neuropathy measures over 2 years. MATERIALS AND METHODS: Participants with type 2 diabetes (n = 78) and controls (n = 26) underwent assessment of clinical and metabolic parameters and neuropathy using corneal confocal microscopy (CCM), vibration perception threshold (VPT), and the DN4 questionnaire at baseline and 2 year follow‐up. RESULTS: Participants with type 2 diabetes had a lower corneal nerve fiber density (CNFD), branch density (CNBD), and fiber length (CNFL) (P ≤ 0.0001) and a higher VPT (P ≤ 0.01) compared with controls. Over 2 years, despite a modest reduction in HbA1c (P ≤ 0.001), body weight (P ≤ 0.05), and LDL (P ≤ 0.05) the prevalence of DPN (P = 0.28) and painful DPN (P = 0.21) did not change, but there was a significant further reduction in CNBD (P ≤ 0.0001) and CNFL (P ≤ 0.05). CNFD, CNBD, and CNFL decreased significantly in physically inactive subjects (P < 0.05–0.0001), whilst there was no change in CNFD (P = 0.07) or CNFL (P = 0.85) in physically active subjects. Furthermore, there was no change in CNFD (P = 0.82), CNBD (P = 0.08), or CNFL (P = 0.66) in patients treated with glucose lowering medication associated with weight loss, whilst CNBD (P = 0.001) decreased in patients on glucose lowering medication associated with weight gain. CONCLUSIONS: In participants with type 2 diabetes, despite a modest improvement in HbA1c, body weight, and LDL there was a progressive loss of corneal nerve fibers; except in those who were physically active or on glucose lowering medication associated with weight loss.
format Online
Article
Text
id pubmed-9533053
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95330532022-10-11 Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes Ponirakis, Georgios Al‐Janahi, Ibrahim Elgassim, Einas Gad, Hoda Petropoulos, Ioannis N Khan, Adnan Ali, Hamda Siddique, Mashhood A Gul, Wajiha Ferdousi, Maryam Kalteniece, Alise Mohamed, Fatima FS Ahmed, Lina HM Dakroury, Youssra El Shewehy, Abeer MM Al‐Mohamedi, Abdulrahman AlMarri, Fatema Homssi, Moayad Qazi, Murtaza Hadid, Nebras H Al‐Khayat, Fatima Mahfoud, Ziyad R Azmi, Shazli Alam, Uazman Zirie, Mahmoud A Al‐Ansari, Yousuf Jayyousi, Amin Rigby, Alan S Kilpatrick, Eric S Atkin, Stephen L Malik, Rayaz A J Diabetes Investig Articles AIMS/INTRODUCTION: Limited studies have identified risk factors linked to the progression of diabetic peripheral neuropathy (DPN) in type 2 diabetes. This study examined the association of risk factors with change in neuropathy measures over 2 years. MATERIALS AND METHODS: Participants with type 2 diabetes (n = 78) and controls (n = 26) underwent assessment of clinical and metabolic parameters and neuropathy using corneal confocal microscopy (CCM), vibration perception threshold (VPT), and the DN4 questionnaire at baseline and 2 year follow‐up. RESULTS: Participants with type 2 diabetes had a lower corneal nerve fiber density (CNFD), branch density (CNBD), and fiber length (CNFL) (P ≤ 0.0001) and a higher VPT (P ≤ 0.01) compared with controls. Over 2 years, despite a modest reduction in HbA1c (P ≤ 0.001), body weight (P ≤ 0.05), and LDL (P ≤ 0.05) the prevalence of DPN (P = 0.28) and painful DPN (P = 0.21) did not change, but there was a significant further reduction in CNBD (P ≤ 0.0001) and CNFL (P ≤ 0.05). CNFD, CNBD, and CNFL decreased significantly in physically inactive subjects (P < 0.05–0.0001), whilst there was no change in CNFD (P = 0.07) or CNFL (P = 0.85) in physically active subjects. Furthermore, there was no change in CNFD (P = 0.82), CNBD (P = 0.08), or CNFL (P = 0.66) in patients treated with glucose lowering medication associated with weight loss, whilst CNBD (P = 0.001) decreased in patients on glucose lowering medication associated with weight gain. CONCLUSIONS: In participants with type 2 diabetes, despite a modest improvement in HbA1c, body weight, and LDL there was a progressive loss of corneal nerve fibers; except in those who were physically active or on glucose lowering medication associated with weight loss. John Wiley and Sons Inc. 2022-06-20 2022-10 /pmc/articles/PMC9533053/ /pubmed/35652859 http://dx.doi.org/10.1111/jdi.13864 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Ponirakis, Georgios
Al‐Janahi, Ibrahim
Elgassim, Einas
Gad, Hoda
Petropoulos, Ioannis N
Khan, Adnan
Ali, Hamda
Siddique, Mashhood A
Gul, Wajiha
Ferdousi, Maryam
Kalteniece, Alise
Mohamed, Fatima FS
Ahmed, Lina HM
Dakroury, Youssra
El Shewehy, Abeer MM
Al‐Mohamedi, Abdulrahman
AlMarri, Fatema
Homssi, Moayad
Qazi, Murtaza
Hadid, Nebras H
Al‐Khayat, Fatima
Mahfoud, Ziyad R
Azmi, Shazli
Alam, Uazman
Zirie, Mahmoud A
Al‐Ansari, Yousuf
Jayyousi, Amin
Rigby, Alan S
Kilpatrick, Eric S
Atkin, Stephen L
Malik, Rayaz A
Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
title Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
title_full Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
title_fullStr Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
title_full_unstemmed Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
title_short Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
title_sort progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533053/
https://www.ncbi.nlm.nih.gov/pubmed/35652859
http://dx.doi.org/10.1111/jdi.13864
work_keys_str_mv AT ponirakisgeorgios progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT aljanahiibrahim progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT elgassimeinas progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT gadhoda progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT petropoulosioannisn progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT khanadnan progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT alihamda progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT siddiquemashhooda progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT gulwajiha progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT ferdousimaryam progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT kalteniecealise progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT mohamedfatimafs progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT ahmedlinahm progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT dakrouryyoussra progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT elshewehyabeermm progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT almohamediabdulrahman progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT almarrifatema progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT homssimoayad progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT qazimurtaza progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT hadidnebrash progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT alkhayatfatima progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT mahfoudziyadr progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT azmishazli progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT alamuazman progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT ziriemahmouda progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT alansariyousuf progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT jayyousiamin progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT rigbyalans progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT kilpatrickerics progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT atkinstephenl progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes
AT malikrayaza progressivelossofcornealnervefibersisassociatedwithphysicalinactivityandglucoseloweringmedicationassociatedwithweightgainintype2diabetes